Neural Therapeutics Inc. Positions Itself at the Forefront of Europe’s Psychedelic and Cannabis Markets
Neural Therapeutics Inc., the Canadian ethnobotanical drug‑discovery company listed on the Canadian National Stock Exchange, has announced a series of developments that place it in a dominant position within two rapidly evolving therapeutic arenas: psychedelic‑assisted medicine and the regulated cannabis sector.
A New Regulatory Landscape for Psychedelics
On 12 October 2025, the European Union enacted sweeping reforms that re‑categorise psychedelic substances such as psilocybin from strictly controlled drugs to “conditionally usable” agents within clinical settings. The change permits psychiatrists and licensed clinicians to prescribe psilocybin for treatment‑resistant depression and other mental health disorders under defined protocols. Germany has already launched a Compassionate‑Use Programme, marking a tangible first step toward mainstream clinical application.
Neural Therapeutics has seized this opportunity, positioning itself as the leading Canadian candidate to bring its ethnobotanical platform into Europe. The company’s press release, issued through the PTANews channel, highlights its readiness to navigate the newly opened regulatory framework and to supply psilocybin‑based therapeutics to EU clinicians. By aligning its R&D pipeline with the updated EU guidelines, Neural Therapeutics aims to secure early‑access approvals and to establish a robust supply chain that meets European quality standards.
Cannabis‑Powered Growth via Hanf.com
In parallel, Neural Therapeutics is capitalising on the European cannabis market through its wholly‑owned subsidiary, CWE European Holdings Inc., operating under the Hanf.com brand. The company reported a 65 % revenue increase to 7.1 million USD (approximately 4.4 million EUR) for the fiscal year ending 31 December 2024. The surge was driven by:
- Expansion of retail footprints – opening new proprietary stores and franchising existing locations across key European markets.
- Enhanced product mix – broadening the wellness catalogue to include a wider range of cannabidiol (CBD) and hemp‑derived offerings.
- Operational efficiency – achieving double‑digit margin growth through streamlined supply‑chain logistics and cost‑control measures.
The cash‑flow performance mirrored the revenue gains, signalling that the business model is not only scalable but also financially robust. Hanf.com’s success provides Neural Therapeutics with a steady revenue stream that can subsidise its research into psychedelic therapeutics, creating a virtuous cycle between commercial activity and innovation.
Strategic Implications for Investors
The confluence of a favourable regulatory environment and a proven commercial engine positions Neural Therapeutics to become a key player in the EU’s mental‑health and cannabis markets. Investors should note:
- Regulatory momentum – EU reforms reduce the barrier to entry for psychedelic therapy, and Neural Therapeutics has already demonstrated the regulatory acumen required to exploit this window.
- Revenue diversification – The Hanf.com subsidiary’s strong financial performance mitigates the high‑risk nature of pharmaceutical development, providing a tangible return on investment while R&D progresses.
- Capital efficiency – Strong cash flow from cannabis retail operations may lower the company’s reliance on external financing, allowing more resources to be devoted to clinical trials and intellectual‑property development.
Looking Ahead
Neural Therapeutics’ next milestones will likely include securing EU market authorisations for its psilocybin‑based product candidates and expanding the Hanf.com retail footprint into additional European jurisdictions. The company’s dual‑track strategy—leveraging regulated cannabis sales to fund psychedelic innovation—illustrates a balanced approach to growth in an industry characterised by both high risk and high reward.
In the coming months, market participants will monitor the company’s progress on regulatory approvals, clinical trial outcomes, and the continued performance of its cannabis‑derived retail operations. Together, these factors will determine whether Neural Therapeutics can sustain its “pole‑position” stance in Europe’s burgeoning bio‑pharmaceutical landscape.
